Dapagliflozin Beneficial for Improving MASH Without Worsening Fibrosis
By Elana Gotkine HealthDay Reporter
FRIDAY, June 6, 2025 -- For patients with metabolic dysfunction-associated steatohepatitis (MASH), treatment with dapagliflozin is beneficial for improvement of MASH without worsening of fibrosis and for improvement of fibrosis without worsening of MASH, according to a study published online June 4 in The BMJ.
Jiayang Lin, from the Nanfang Hospital of Southern Medical University in Guangzhou, China, and colleagues examined the efficacy and safety of the sodium-glucose cotransporter 2 inhibitor dapagliflozin in participants with MASH in a multicenter, double-blind, randomized trial conducted in six tertiary hospitals in China. One hundred fifty-four adults with biopsy-diagnosed MASH were randomly assigned to receive 10 mg orally of dapagliflozin or matching placebo once daily for a 48-week period. MASH improvement (defined as a decrease of ≥2 points in nonalcoholic fatty liver disease activity score [NAS] or a NAS of ≤3 points) without worsening of fibrosis was the primary end point.
The researchers found that 53 percent of the 78 participants in the dapagliflozin group and 30 percent of the 76 participants in the placebo group had MASH improvement without worsening of fibrosis (risk ratio, 1.73), with a mean difference in NAS of −1.39. MASH resolution without worsening of fibrosis occurred in 23 and 8 percent of participants in the dapagliflozin and placebo groups, respectively (risk ratio, 2.91). Fibrosis improvement without worsening of MASH was reported in 45 and 20 percent of participants in the dapagliflozin and placebo groups, respectively (risk ratio, 2.25). Overall, 1 and 3 percent of patients in the dapagliflozin and placebo groups, respectively, discontinued treatment because of adverse events.
"These results support the potential for dapagliflozin to provide benefit to patients with MASH and liver fibrosis," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
Degree of Weight Loss Affects Tirzepatide-Linked Cardiometabolic Risk Improvement
TUESDAY, July 1, 2025 -- For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction...
Self-Esteem Scores Soar One Year After Metabolic, Bariatric Surgery
TUESDAY, June 24, 2025 -- Self-esteem scores increase after metabolic and bariatric surgery (MBS), with greater improvement in scores for those with higher postoperative weight...
Minor Complications Up for Black Patients After Weight-Loss Surgery
MONDAY, June 23, 2025 -- Black patients have a higher incidence of minor complications after metabolic and bariatric surgery, according to a study presented at the annual meeting...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.